AI-Powered Drug Gets Green Light for Pediatric Brain Cancer Trial

DALLAS, TX – March 27, 2026 – Federal regulators have cleared the path for a new clinical trial targeting some of the most devastating forms of childhood cancer, offering a potential new lifeline for children with relapsed or refractory brain and spinal cord tumors. Lantern Pharma and its subsidiary, Starlight Therapeutics, announced that the U.S. Food and Drug Administration (FDA) has given its approval for an Investigational New Drug (IND) application, allowing them to proceed with a Phase 1 trial for STAR-001.

This clearance represents a critical step forward in a field where progress has been painfully slow. Pediatric central nervous system (CNS) tumors are the leading cause of cancer-related death in children and adolescents in the United States, surpassing leukemia. For many of these young patients, particularly those with aggressive or recurrent cancers like Diffuse Intrinsic Pontine Glioma (DIPG) or Atypical Teratoid/Rhabdoid Tumor (ATRT), the prognosis remains catastrophic, with survival often measured in months and curative options nonexistent.

The planned trial aims to evaluate STAR-001, a precision oncology compound, both as a standalone treatment and in a novel combination with an existing drug, spironolactone. What sets this effort apart is its origin story: the drug's potential and its unique combination strategy were identified not through conventional lab screening alone, but with the guidance of a powerful artificial intelligence platform.

A Desperate Need for Innovation

For families navigating a pediatric CNS cancer diagnosis, the landscape of available treatments is fraught with limitations. Standard therapies, including surgery, radiation, and chemotherapy, have reached a ceiling of efficacy for many high-grade tumors. Surgical removal is often impossible for tumors located in critical areas of the brainstem, like DIPG. Furthermore, the blood-brain barrier, a protective membrane surrounding the brain, effectively blocks many chemotherapy drugs from reaching their target.

Even when treatments show some effect, they can leave a wake of severe, long-term toxicities that impact a child's development and quality of life. For children whose cancer returns, the options dwindle dramatically. DIPG, for instance, is considered universally fatal, with a median survival of less than a year. For relapsed ATRT, glioblastoma (GBM), medulloblastoma, and ependymoma, the outlook is similarly grim.

This stark reality has fueled a desperate search for new therapeutic approaches that are not only more effective but also more targeted. The development of STAR-001 is a direct response to this urgent, unmet need, aiming to exploit the specific biological wiring of these cancer cells while sparing healthy tissue.

The AI-Driven Breakthrough

The scientific foundation for the STAR-001 trial was built with the help of Lantern Pharma’s proprietary AI platform, RADR®. This sophisticated system sifts through more than 200 billion oncology-specific data points, using machine learning to uncover biological patterns, predict patient responses, and identify novel therapeutic strategies that might otherwise be missed. RADR® analyzed vast genomic and molecular datasets to pinpoint a key vulnerability in many pediatric CNS tumors: the overexpression of an enzyme called Prostaglandin Reductase 1 (PTGR1).

STAR-001 is an acylfulvene-based agent specifically engineered to be a prodrug. It remains inert until it encounters cells with high levels of PTGR1. Inside the cancer cell, the enzyme activates STAR-001, converting it into a potent compound that causes extensive DNA damage, ultimately triggering cell death. This precision bioactivation mechanism is designed to make the therapy highly selective for tumors while minimizing harm to normal tissues with low PTGR1 levels.

“This IND clearance is a defining milestone for Starlight Therapeutics and a meaningful step forward for pediatric neuro-oncology,” said Panna Sharma, CEO of Lantern Pharma and Chairman of Starlight Therapeutics. “For children with relapsed or refractory CNS tumors, the options are desperately limited — and the science behind this planned trial was built to change that.”

A Novel Two-Pronged Attack

The innovation extends beyond the drug itself. The RADR® platform also identified a critical escape route that cancer cells use to survive DNA damage: a repair pathway involving an enzyme called ERCC3. To block this escape, the trial will test STAR-001 in combination with spironolactone, a well-established, brain-penetrant oral medication with a long history of safe use in children for other conditions.

In this context, spironolactone is being repurposed to act as a saboteur. Preclinical studies have shown it effectively degrades ERCC3, dismantling the cancer cell’s primary DNA repair machinery. The strategy is a classic one-two punch: STAR-001 delivers the damage, and spironolactone ensures it cannot be repaired. This synthetic lethality approach forces the cancer cell into an unrecoverable state of crisis.

The preclinical results for this combination are striking. In animal models of ATRT, the addition of spironolactone to STAR-001 extended median survival by 181% compared to the control group. In models of medulloblastoma and other aggressive brain tumors, the combination led to a three- to five-fold increase in cancer cell death compared to STAR-001 alone.

“Our modeling, analysis and subsequent in-vivo and animal studies showed that spironolactone could dismantle that pathway by degrading ERCC3 before STAR-001 even enters the cancer cell,” Sharma explained. “We believe this represents a genuinely new way to attack these brain cancers.”

A Collaborative Path to the Clinic

To bring this promising science to patients, Starlight Therapeutics is partnering with the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC), a network of 14 leading academic children’s cancer centers across the United States, Canada, and Israel. This collaboration provides the infrastructure and expertise necessary to conduct a complex, early-phase trial for a rare disease population. Member institutions include renowned centers like MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Lucile Packard Children’s Hospital at Stanford.

The Phase 1 trial is designed to enroll between 18 and 42 pediatric patients from ages 1 to 17. Its primary goals will be to determine the safety, tolerability, and appropriate dose of STAR-001, both as a single agent and in combination with spironolactone.

“STAR-001 is a novel, precision brain-penetrant alkylator… that has demonstrated meaningful activity across multiple malignant pediatric brain tumor types in preclinical models,” noted Dr. Marc Chamberlain, Chief Medical Officer of Starlight Therapeutics. “We look forward to initiating this planned trial and to the possibility of delivering a new therapeutic option to children who need it most.”

The initiation of the trial, which is subject to securing additional funding, marks a moment of tangible hope. It represents the culmination of an innovative, AI-guided discovery process and a collaborative effort to translate that science into a potential treatment for children facing the most challenging of diagnoses.